Abstract
Glioblastoma (GBM) is the most malignant and deadly brain tumor. Even with standard treatment, virtually all GBMs recur in months. High-throughput studies of GBMs resulted in several molecular classifications based on mRNA levels (transcriptome), however, they have not been useful in the clinic. One possible factor is that the final functional product of most genes is a protein. Our labor…